Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat and azacitidine in advanced myelodysplastic syndrome
NCT03047993Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telaglenastat in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2017; status: completed.
02
Drugs
telaglenastat
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03047993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03047993.